SPI-077 B103

formulation of cisplatin encapsulated in pegylated STEALTH liposomes containing unsaturated phospholipids

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Neoplasms (Cancer) 04/01/2004 - "Cisplatin (10 mg/kg), SPI-077 (10 mg/kg), and SPI-077 B103 (5 mg/kg) were administered i.v. to mice bearing B16 murine melanoma tumors. " 04/01/2004 - "This study suggests that more SPI-077 and SPI-077 B103 distribute into tumors, but release less Pt into tumor ECF, and form fewer Pt-DNA adducts than does cisplatin." 04/01/2004 - "SPI-077 and SPI-077 B103 are formulations of cisplatin encapsulated in pegylated STEALTH liposomes that accumulate in tumors. "
2.	Melanoma (Melanoma, Malignant) 04/01/2004 - "Cisplatin (10 mg/kg), SPI-077 (10 mg/kg), and SPI-077 B103 (5 mg/kg) were administered i.v. to mice bearing B16 murine melanoma tumors. "